The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...

Italy’s Axxam and Molecular Health have partnered to identify and validate new therapeutic targets in drug development.

China’s NMPA has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic ...

AI is revolutionizing the pharma supply chain by automating manual tasks, monitoring risks and providing predictive insights.

Digital innovations such as ePRO and eCOA are streamlining clinical trials, boosting participant engagement, and improving ...

Agenus has signed $141m partnership agreements with Zydus Lifesciences and its subsidiaries to enhance clinical developments ...

The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).

Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of ...